StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note released on Wednesday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Price Performance

Shares of NYSE:ENZ opened at $0.73 on Wednesday. Enzo Biochem has a 52 week low of $0.68 and a 52 week high of $1.50. The company’s 50 day moving average is $1.04 and its two-hundred day moving average is $1.09.

Enzo Biochem (NYSE:ENZ) last posted its earnings results on Monday, December 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative net margin of 81.73% and a negative return on equity of 11.84%.

Enzo Biochem Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were paid a dividend of $0.10 per share. This represents a $0.40 annualized dividend and a yield of 55.03%. The ex-dividend date of this dividend was Friday, November 15th.

Institutional Trading of Enzo Biochem

Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its holdings in shares of Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares during the last quarter. XTX Topco Ltd boosted its position in shares of Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares during the period. BBR Partners LLC purchased a new position in Enzo Biochem during the 3rd quarter worth approximately $112,000. Finally, Geode Capital Management LLC increased its position in Enzo Biochem by 3.3% during the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after buying an additional 11,742 shares during the period. Hedge funds and other institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.